JAB-3312
Phase 3Small molecule
JAB-3312 is one of 35 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
1
Indications
5
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
JAB-3312
AAllist Pharmaceuticals, Inc.
Phase 3
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
REGN2810
RegeneronPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JAB-3312. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAllist Pharmaceuticals, Inc.